

PTO/SB/08B (09-06) Approved for use through 03/31/2070, 0MB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid DMI control number.

Complete if Known Application Number 10/570,737 Filing Date INFORMATION DISCLOSURE September 8, 2004 STATEMENT BY APPLICANT First Named Inventor Raphael Mechoulam Art Unit N/A (Use as many sheets as necessary) Examiner Name N/A Attorney Docket Number Sheet of 4 0-06-058/16434/US/03

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	١	BISOGNO, TIZIANA et al., British Journal of Pharmacology, 134 (4):845-852 (2001) XP002319199	
	2	CASU, M. A. et al. (2003) Eur. J. Pharmacol. 459(1): 97-105	
, ,,	3	CHESHER, G. B. et al. (1973) Br. J. Pharmacol. 49(4): 588-94	
	4	COLOMBO, G. et al. (1998) Eur. J. Pharmacol. 344(1): 67-9	
,	5	FRIDE, E. (1995) Brain Res. 697, 83	
	Q	FRIDE, E. (2002) Endocannabinoids in the central nervous system - an overview. Prostaglandins, Leukotrienes and Essential Fatty Acids	
	7	FRIDE, E. and C. SANUDO-PENA (2002) Cannabinoids and endocannabinoids: behavioral and developmental aspects. In: The Biology of Marijuana, ed. E. Onaivi, Harwood Academic	
		Publishers, Reading	
	8	FRIDE, E. and R. MECHOULAM (1993) Eur. J. Pharmacol. 231, 313	
	9	GALIEGUE, S. et al. (1995) Eur. J. Biochem. 232(1): 54-61	

Examiner	/Toby Hain/	Date	09/10/2009
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to application. It is placed in the property of Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## Receipt date: 04/06/2007

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

	er the Paperwork Red	uction Ac	t of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Jubantur	e 101 101111 1445/F 10			Application Number	10/570,737	
INFO	DRMATION	DIS	CLOSURE	Filing Date	September 8, 2004	
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Raphael Mechoulam	
	(Use as many she	ato on m	occessed.	Art Unit	N/A	
	(Use as many sne	uis ds n	ocossary,	Examiner Name	N/A	
Sheet	2	of	4	Attorney Docket Number	0-06-058/16434/US/03	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	10	GARDNER, A.L. et al. (1988) Trends Pharmacol. Sci. Suppl.: 40-3	
	11	GRIFFIN, G. et al. (1997) Eur. J. Pharmacol. 339, 53	
	12	GURWITZ, D. et al. (1994) Eur. J. Pharmacol. 267, 21	
	13	HAEFELY, W. et al. (1990) Trends Pharmacol. Sci. 11(11): 452-6	
•	14	HANUS, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 14228	
	15	HERKENHAM, M. (1995) Cannabinoid receptors, London, Academic Press: 145-166	
	16	IZZO, A. et al. (2000) Br. J. Pharmacol. 129(8): 1627-32	
	17	IZZO, A.A. et al. (2001) Br. J. Pharmacol. 132, 1411	
	18	JOHNSON, M.R. and MELVIN, L.S. (1986) The discovery of non-classical cannabinoids analgetics. In: Cannabinoids as therapeutic agents. Ed. R.	
	19	Mechaulam, CK5 Press FL, rk 121-145 LANDI, M. et al. (2002) Eur. J. Pharmacol. 450, 77	

Examiner Signature	/Toby Hain/	Date Considered	09/10/2009
			to do the self-self-self-self-self-self-self-self-

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consources, include copy or tim storm with next communication to applicant. In Japiciant's uring excitation designation number (optional), 2-Applicant is to place a check mark here if English language Transfallor is attached. This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 58 USS. 1.22 and 37 CFR 11.4. This collection is estimated to late 2-bours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the mount of time you require to complete in from another supplessions for reducing this burden, should be sent to the Chief Hormalico Officer, US-3 Intert and Trademark Office, P.O. Bos. 1450, Alexandria, VA 2231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS AUDRESS. SEND TO: Commissioner of Patents, P.O. Bos. 1450, Alexandria, VA 2231-1450, VA 2231-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Receipt date: 04/06/2007

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Und	der the Paperwork Red	duction A	d of 1995, no persons a		of information unless it contains a valid OMB control number.	
Substitut	te for form 1449/PTO			Complete if Known		
Cubsinu	101011011111144011170			Application Number	10/570,737	
INFO	ORMATION	I DIS	CLOSURE	Filing Date	September 8, 2004	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Raphael Mechoulam	
	(Use as many she			Art Unit	N/A	
	(USe as many sne	991S 45 II	ocessary)	Examiner Name	N/A	
Sheet	3	of	4	Attorney Docket Number	0-06-058/16434/US/03	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	20	MALFAIT, A.M. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 9561	į
	21	MARTIN, B. R. et al. (1991) Pharmacol. Biochem. Behav. 40(3): 471-8	
	22	MECHOULAM, R. et al. (1998) Prog. Med. Chem. 35, 199	
		MEGHOULAM, R. GDC-Press Fl., pp. 121-145	
	23	PARKER, L.A. et al. (2002) Neuroreport 13, 567	
	24	PERTWEE, R.G. (1997) Pharmacol. Ther. 74, 129	
	25	PERTWEE, R.G. (2001) Gut 48(6): 859-67	
	26	PINTO, L. (2002) Prostaglandins Leukot Essent Fatty Acids 66, 333	
	27	ROBSON, P. (2001) Br. J. Psychiatry 178, 107	
	28	TJOLSEN, A. and HOLE (1997) The Pharmacology of Pain, Springer, Heidelberg, pp.1-20]	

Examiner	/Toby Hain/	Date	09/10/2009
Signature	1100j Halli	Considered	00, 10, 2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicate.

Applicant is up present or check may be represented by a property of the property

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Receipt date: 04/06/2007

PTO/SB/08B (09-06) Approved for use through 03/31/2007. OMB 0651-0031

Substitute for form 1449/PTO  Application Number 10/570 737	
Application Number 10/570,737	
INFORMATION DISCLOSURE Filing Date September 8, 2004	
STATEMENT BY APPLICANT First Named Inventor Raphael Mechoulam	
Art Unit N/A	
(Use as many sheets as necessary)  Examiner Name  N/A	
Sheet 2 of 4 Attorney Docket Number 0-06-058/16434/US/03	$\overline{}$

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	29	Young, J. M. et al. (1984) J. Invest. Dermatol. 82, 367-71	
*			

Examiner Signature	/Toby Hain/	ate Considered	09/10/2009

EVEX.NIMER. I initial if reference occasioned, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includes only of the form wheth the communication to applicate.

FEX.NIMER. I initial inference occasional initial interest in the conformance and not considered. Include only of the communication of the conformance of the conformance and not considered in the communication of the conformance and not considered in the communication of the conformance and not represent the communication of the conformance and not be completed in the communication of the completed application from the the USPTO. Time was well explending upon the includination case. Any comments on the emount of time you require to complete this form and/or suggestion for reducing his busines, about the to the Chief Information Officer, U.S. Patient end Tredemark Officer, 6-0 Bost 1450, Assentiate, V.A. 2513-1450, D.D. ONT CSROTP. ESE OR COMMETTED FORMS TO THIS ADDRESS. SENIOR.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.